A retrospective study of the SARS-CoV-2 Alpha Variant: Epidemiological profile and impact of vaccination in Morocco. | ||
| Microbes and Infectious Diseases | ||
| Volume 6, Issue 4, November 2025, Pages 6189-6201 PDF (921.33 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/mid.2025.390711.2845 | ||
| Authors | ||
| Youssef IKKEN* 1, 2; Souad El HASSANI3; Mounir RACHID4; Samia Boussaa2; Bouchra ASSARAG5; Majdouline OBTEL1; Abdelghafour MARFAK5 | ||
| 1Laboratory of Biostatistics, Clinical Research and Epidemiology and Laboratory of Community Health, Preventive Medicine and Hygiene, Department of Public health / Pedagogy and Research Unit of Public Health, Department of Public health research team, Faculty of Medicine and Pharmacy of Rabat, Mohammed V University in Rabat, Morocco. | ||
| 2Research Team, ISPITS - Higher Institute of Nursing Professions and Health Techniques in Rabat, Ministry of Health and Social Protection, Rabat, Morocco. | ||
| 3Public Health and Epidemiological Surveillance Team, Regional Department of Health and Social Protection, Rabat-Sale-Kenitra, Ministry of Health and Social Protection, Rabat, Morocco. | ||
| 4Laboratory of Earthworm, Improving Soil Productivity and Environment (LAPSE), Faculty of Sciences of Rabat, Mohammed V University in Rabat, Morocco | ||
| 5National School of Public Health, Rabat, Morocco. | ||
| Abstract | ||
| Background: The Variant of Concern, such as the SARS-CoV-2 Alpha Variant, was first identified in Morocco on 29 December 2020. The present study aimed to analyze the epidemiological profile, and the vaccination status of patients with the Alpha Variant during the COVID19 pandemic in Morocco. Methods: A retrospective analytical study was conducted in the Rabat-Sale-Kenitra Region, central of Morocco and included all reported cases of Alpha Variant. The data analysis was anonymized, compiled in Excel, and processed by SPSS software. Results: The 545 Alpha Variant patients were registered in the study area. Mean age and sex ratio (Male/Female) were 38±18 years and 0.73 (230/315), respectively. Average cumulative incidence of new cases during 4 months and 7 days was 25.32 per 1000000 persons. Vaccinated population was 81 (14.86%) versus a non-vaccinated population of 464 (85.14%). The cure and fatality rates were 99.45% and 0.55%, respectively. Conclusion: The analysis showed that patients over the age of 38 with comorbidities are at high risk of developing symptoms if they contract the SARS-CoV-2 variant. In contrast, we found that the second dose of the SARS-CoV-2 vaccine was a protective factor for the symptomatology, the hospitalization and also attenuate the effects of the disease. | ||
| Keywords | ||
| Anti-SARS-CoV-2 vaccine; Dose-Effects vaccine; Epidemiologic Profile; SARS-CoV-2 Alpha Variant; Symptomatology | ||
|
Statistics Article View: 321 PDF Download: 71 |
||
